Africa Corporate Wellness Market, by End User, 2018-2027
| Label | USD Million |
|---|---|
| 2018 | 306.194939782208 USD Million |
| 2019 | 330.731000677609 USD Million |
| 2020 | 357.16131475965 USD Million |
| 2021 | 385.628356113166 USD Million |
| 2022 | 416.285109858492 USD Million |
| 2023 | 441.173370022175 USD Million |
| 2024 | 467.30025853885 USD Million |
| 2025 | 494.956093584054 USD Million |
| 2026 | 524.750375790691 USD Million |
| 2027 | 556.317041735189 USD Million |
| 2028 | 589.759963851888 USD Million |
| 2029 | 625.811373393845 USD Million |
| 2030 | 664.040413080076 USD Million |
| 2031 | 704.57665215543 USD Million |
| 2032 | 747.557219517284 USD Million |
Data Source: Wantstats Repository
Market Dynamics
The pharmacovigilance market outlook for Germany in 2018 to 2032 firmly places it on a par with other European countries, and even the developed world in terms of drug safety regulations. The German regulatory system is highly structured and robust and is known for its scientific rigor. As with other countries, German regulators adhere to International Conference on Harmonization (ICH) guidelines on drug safety monitoring and evaluation. In line with the broader trends in healthcare, the pharmacovigilance market in Germany is expected to witness positive growth over the next decade. With increasing prevalence of chronic diseases, regulatory requirements are likely to be intensified to ensure the safety of drugs available in the German market. At the same time, the rise of technology-assisted systems such as electronic prescribing, electronic health records and automated reporting systems should lead to further efficiencies in drug safety oversight. In addition, private players are expected to play an increasingly important role in Germany's pharmacovigilance market, as they are likely to venture into the market for compliance and specialist services. This includes undertaking pre- and post-marketing studies to confirm the safety of drugs.
Moreover, with the amendments to the German Drug Act, there is likely to be an increased number of post-marketing surveillance studies to monitor the safety of drugs. The German government has also formulated guidelines related to regulatory compliance for medicines, biologics and biosimilars. This should encourage greater participation of the German pharmaceutical industry in pharmacovigilance activities. Finally, greater awareness among healthcare professionals, as well as among patients and consumers, is also likely to be a major factor in Germany's pharmacovigilance market in the years to come. Overall, the pharmacovigilance market outlook for Germany in 2018 to 2032 is expected to remain positive, with an increasing focus on drug safety regulation. The increasing role of technology, combined with regulations and guidelines for drug safety oversight, should drive growth in the coming years.
Research Methodology
Figures reflect Wantstats’ original market research and forecasting models, compiled as part of the Wantstats research archive and published in 2023.
Unlock the Full Data
Get This Chart
Access the complete chart and underlying data to support your research, analysis, and business decisions.
Powering the world's best teams.
From next-gen startups to established enterprises.
Get in Touch
Let's work together
support@wantstats.comSee our work in action
Start your data driven journey with us!
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence



